Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

BPC-157 vs TB-500

Comparison

BPC-157 and TB-500 are two peptides people frequently compare. BPC-157 is a peptide people use to speed up recovery from soft-tissue injuries like tendon, ligament, and muscle damage. It's also used for gut inflammation and ulcer healing. Not FDA-approved; most… TB-500 is a peptide people use to speed recovery from tendon, muscle, and wound injuries, and to support athletic performance. It works by activating pathways that promote the formation of new blood…

BPC-157 TB-500
What it is BPC-157 is a peptide people use to speed up recovery from soft-tissue injuries like tendon, ligament, and muscle damage. It's also used for gut inflammation and ulcer healing. Not FDA-approved; most… TB-500 is a peptide people use to speed recovery from tendon, muscle, and wound injuries, and to support athletic performance. It works by activating pathways that promote the formation of new blood…
Primary uses
  • Interstitial cystitis (bladder pain syndrome)
  • Musculoskeletal soft tissue healing (tendon, ligament, skeletal muscle, bone)
  • Wound healing (skin, gastrointestinal, and other tissues)
  • Gastrointestinal anastomosis healing and fistula therapy
  • Tendon healing / Achilles tendon repair
  • Wound healing / angiogenesis / tissue repair
  • Musculoskeletal recovery and athletic performance
  • Healthy aging / gerontology
How it works It's also used for gut inflammation and ulcer healing. Not FDA-approved; most research is in animals, with a few small human studies. It works by activating pathways that promote the formation of new blood vessels and tissue repair. Not FDA-approved; banned by WADA; sold as a gray-market research compound.
Common dose 250 mcg, subcutaneous injection, once daily 2.0-2.5 mg, subcutaneous injection, twice per week
FDA status Not approved by the US Food and Drug Administration for any therapeutic indication (PMID: 39325560, PMID: 40005999, PMID: 42198317). No completed Phase II clinical trial as of the reviewed literature. Not approved for human use by the FDA. Reviewed literature describes TB-500 as an unapproved, investigational compound operating in a 'gray market'. One review notes most of these therapies remain…
Evidence level Human observational Mixed